Choose A Condition: PLEASE SELECT MODERATELY TO SEVERELY ACTIVE RA ACTIVE PSORIATIC ARTHRITIS ACTIVE ANKYLOSING SPONDYLITIS Home About SIMPONI ARIA® Efficacy ACR Response in RA Inhibition of Radiographic Progression in RA HAQ-DI Scores in RA SF-36 Scores in RA FACIT-F Scores in RA Safety Safety Profile in RA: Placebo-Controlled Phase Safety Profile in RA: Controlled and Uncontrolled Phase Home About SIMPONI ARIA® Efficacy ACR Response in PsA Inhibition of Radiographic Progression in PsA Enthesitis/Dactylitis in PsA PASI Response in PsA HAQ-DI in PsA SF-36 Scores in PsA FACIT-F Scores in PsA Safety Safety Profile in PsA: Placebo-Controlled Phase Saftey Profile in PsA: Controlled and Uncontrolled Phase Home About SIMPONI ARIA® Efficacy ASAS Response BASDAI Scores BASFI/BASMI Scores ASQoL Scores SF-36 Scores in AS ASAS Partial Remission Data Safety Safety Profile in AS: Placebo-Controlled Phase Safety Profile in AS: Controlled and Uncontrolled Phase Home Efficacy Safety Dosing and Administration Dosing Dosing Calculator Interactive Infusion Video Administration Instructions Access and Affordability First-line Access Local Coverage Contract Purchase Program Resources And Support Janssen CarePath Additional Resources Important Safety Information Medical Information Center Request Information Patient Website
FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE RA, IN COMBINATION WITH MTX SIMPONI ARIA® is ready to fight the symptoms of moderately to severely active RA. ABOUT SIMPONI ARIA® Learn about the only fully human anti-TNFα IV therapy DEMONSTRATED EFFICACY Explore RA treatment results for SIMPONI ARIA® + MTX from a clinical trial PATIENT-REPORTED OUTCOMES (PROs) Learn more about the SIMPONI ARIA® PRO data for HAQ-DI, SF-36, and FACIT-F in a clinical trial. SEE RESULTS DOSING CALCULATOR Calculate an adult patient's dose of SIMPONI ARIA® based on weight. GET STARTED ACCESS AND AFFORDABILITY View first-line coverage rates for SIMPONI ARIA®. LEARN MORE
PATIENT-REPORTED OUTCOMES (PROs) Learn more about the SIMPONI ARIA® PRO data for HAQ-DI, SF-36, and FACIT-F in a clinical trial. SEE RESULTS